Compare Summit Therapeutics Inc (SMMT) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Workiva Inc — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Workiva Inc trades at $55.02 (market cap $3.21B). The key difference: Summit Therapeutics Inc is far larger — about 3.3× Workiva Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | WK | |
|---|---|---|
Market Cap | $10.48B | $3.21B |
Sector | Health | Technology |
52-Week High | $29.32 | $93.31 |
52-Week Low | $13.05 | $44.31 |
Enterprise Value | $9.90B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Workiva (WK) trades at $57.19, up 0.02% on the day, with a bullish technical outlook from moving averages and strong analyst support. The company shows robust revenue growth, reaching $884.57M in 2025, and has consistently beaten earnings estimates in recent quarters. Recent news highlights its AI-powered platform growth and upcoming Q2 2026 results.
The stock presents a positive outlook with an 88.89% buy rating from analysts and a consensus price target of $71.00, suggesting 24% upside. Risks include high valuation multiples (P/E 238.29) and profitability challenges, with net income margin at 1.53% for 2026. Investors should weigh growth potential against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
